Table 2 Clinicopathological comparison... | American Society of Hematology

Table 2

Clinicopathological comparison among PD-L1 expression patterns in ATLL

			nPD-L1 negative (n = 125)				P
	nPD-L1 positive (n = 10)		miPD-L1 positive (n = 79)		PD-L1 negative (n = 46)		nPD-L1+ vs nPD-L1−	miPD-L1 + vs PD-L1−
Characteristic	No.	%	No.	%	No.	%	P*	P†
Sex (male/female)	7/3	70/30	40/39	51/49	29/17	63/73	.51‡	.18
Age, y
Median (range)	66 (47–82)		66 (35–90)		64 (40–86)		.78	.34
ECOG PS, 2-4	5	50	26/77	34	12/45	27	.29‡	.41
Shimoyama classification							.39	.43
Smoldering type	0	0	2/67	3	0/34	0
Acute type	7	70	30/67	45	16/34	47	[.20‡]	[.93]
Lymphoma type	3	30	35/67	52	18/34	53	[.20‡]	[.93]
B symptoms	5	50	26/74	35	11	24	.29‡	.91
Elevated serum LDH	6	60	43	54	28	61	1.00‡	.48
Hypercalcemia	2	20	8	10	11	24	.65‡	.04
Elevated CRP	8	80	44/76	58	28	61	.31‡	.75
Ann Arbor stage, III or IV	10	100	64/78	82	39	85	.36‡	.69
Peripheral blood involvement	6	60	41/76	54	23	50	.75‡	.67
Bone marrow involvement	4/7	57	19/65	29	7/34	21	.098‡	.35
Skin lesion	1	10	19/78	24	3	7	1.00‡	.01‡
WBC, ×10⁹/L, median (range)	14.8 (2.9-48.3)		8.6 (1.2-97.1)		9.4 (1.6-45.9)		.17	.55
Hemoglobin, g/dL, median (range)	12.0 (7.7-14.7)		12.4 (6.3-16.1)		13.2 (8.0-18.6)		.49	.052
Platelets, ×10⁹/L, median (range)	193 (65-370)		222 (19-538)		240 (22-840)		.24	.46
IPI risk group, high (3-5)	9	90	42/74	57	27/45	60	.09*	.73
JCOG-PI, high	5/10	50	28/77	36	19/45	42	.51	.52
Treatment
Chemotherapy	8	80	69/78	89	40/45	89	.34‡	.94
Radiotherapy	0	0	9/77	12	5/44	11	.60‡	1.00
Transplantation	1	10	10/77	13	8/44	18	1.00‡	.45
No therapy	2	20	9/78	12	2/45	4	.25‡	.33
CR or CR(u)	2/8	25	22/67	33	11/41	27	1.00‡	.51
Morphological classification							.51	.54
Small-cell variant	0	0	2	3	1	2
Medium-cell variant	2	20	19	24	7	15
Large-cell variant	2	20	31	39	24	52
Hodgkin-like variant	0	0	2	3	0	0
Anaplastic variant	1	10	5	6	3	7
Pleomorphic variant	5	50	20	25	11	24
IHC
Neoplastic cells
PD-1, positive	0	0	16	20	9	20	.21‡	.93
CD30, positive	5	50	20	25	11	24	.13‡	.86
CCR4, positive	10	100	72	91	44	96	1.00‡	.48‡
FoxP3, positive	2	20	21	27	12	26	1.00‡	.95
PD-1 positive TIL, counts/HPF, average (range)	3.0 (0-24.4)		3.6 (0-38.4)		0.3 (0-5.2)		.16	.0009

			nPD-L1 negative (n = 125)				P
	nPD-L1 positive (n = 10)		miPD-L1 positive (n = 79)		PD-L1 negative (n = 46)		nPD-L1+ vs nPD-L1−	miPD-L1 + vs PD-L1−
Characteristic	No.	%	No.	%	No.	%	P*	P†
Sex (male/female)	7/3	70/30	40/39	51/49	29/17	63/73	.51‡	.18
Age, y
Median (range)	66 (47–82)		66 (35–90)		64 (40–86)		.78	.34
ECOG PS, 2-4	5	50	26/77	34	12/45	27	.29‡	.41
Shimoyama classification							.39	.43
Smoldering type	0	0	2/67	3	0/34	0
Acute type	7	70	30/67	45	16/34	47	[.20‡]	[.93]
Lymphoma type	3	30	35/67	52	18/34	53	[.20‡]	[.93]
B symptoms	5	50	26/74	35	11	24	.29‡	.91
Elevated serum LDH	6	60	43	54	28	61	1.00‡	.48
Hypercalcemia	2	20	8	10	11	24	.65‡	.04
Elevated CRP	8	80	44/76	58	28	61	.31‡	.75
Ann Arbor stage, III or IV	10	100	64/78	82	39	85	.36‡	.69
Peripheral blood involvement	6	60	41/76	54	23	50	.75‡	.67
Bone marrow involvement	4/7	57	19/65	29	7/34	21	.098‡	.35
Skin lesion	1	10	19/78	24	3	7	1.00‡	.01‡
WBC, ×10⁹/L, median (range)	14.8 (2.9-48.3)		8.6 (1.2-97.1)		9.4 (1.6-45.9)		.17	.55
Hemoglobin, g/dL, median (range)	12.0 (7.7-14.7)		12.4 (6.3-16.1)		13.2 (8.0-18.6)		.49	.052
Platelets, ×10⁹/L, median (range)	193 (65-370)		222 (19-538)		240 (22-840)		.24	.46
IPI risk group, high (3-5)	9	90	42/74	57	27/45	60	.09*	.73
JCOG-PI, high	5/10	50	28/77	36	19/45	42	.51	.52
Treatment
Chemotherapy	8	80	69/78	89	40/45	89	.34‡	.94
Radiotherapy	0	0	9/77	12	5/44	11	.60‡	1.00
Transplantation	1	10	10/77	13	8/44	18	1.00‡	.45
No therapy	2	20	9/78	12	2/45	4	.25‡	.33
CR or CR(u)	2/8	25	22/67	33	11/41	27	1.00‡	.51
Morphological classification							.51	.54
Small-cell variant	0	0	2	3	1	2
Medium-cell variant	2	20	19	24	7	15
Large-cell variant	2	20	31	39	24	52
Hodgkin-like variant	0	0	2	3	0	0
Anaplastic variant	1	10	5	6	3	7
Pleomorphic variant	5	50	20	25	11	24
IHC
Neoplastic cells
PD-1, positive	0	0	16	20	9	20	.21‡	.93
CD30, positive	5	50	20	25	11	24	.13‡	.86
CCR4, positive	10	100	72	91	44	96	1.00‡	.48‡
FoxP3, positive	2	20	21	27	12	26	1.00‡	.95
PD-1 positive TIL, counts/HPF, average (range)	3.0 (0-24.4)		3.6 (0-38.4)		0.3 (0-5.2)		.16	.0009

Abbreviations are explained in Table 1.

nPD-L1 positive versus nPD-L1 negative.

†

miPD-L1 positive versus PD-L1 negative.

‡

Fisher’s exact test; values in brackets indicate P value between acute type and lymphoma type.

View Large

This Feature Is Available To Subscribers Only